Top

Published in:

Open Access 01-12-2018 | Research

CCR5del32 genotype in human enteroviral cardiomyopathy leads to spontaneous virus clearance and improved outcome compared to wildtype CCR5

Authors: Dirk Lassner, Christine S. Siegismund, Uwe Kühl, Maria Rohde, Andrea Stroux, Felicitas Escher, Heinz-Peter Schultheiss

Published in: Journal of Translational Medicine | Issue 1/2018

Abstract

Background

Enteroviral cardiomyopathy is a life-threatening disease, and detection of enterovirus (EV) RNA in the initial endomyocardial biopsy is associated with adverse prognosis and increased mortality. Some patients with EV infection may spontaneously eliminate the virus and recover, whereas those with virus persistence deteriorate and progress to heart failure. Interferon-beta (IFN-β) therapy eliminates the virus, resulting in increased survival of treated patients. CCR5 is expressed on antigen-presenting cells (both macrophages and dendritic cells) and immune effector cells (T-lymphocytes with memory/effector phenotype and natural killer cells). Its 32-bp deletion (CCR5del32) is the most frequent human coding sequence mutation. This study addresses the correlation of CCR5 polymorphism to the clinical course of EV infection and the necessity for IFN-β treatment.

Methods

We examined 97 consecutive patients with chronic/inflammatory cardiomyopathy and biopsy-proven EV infection and reliable information on clinical outcomes by CCr5 genotyping. These data were evaluated in relation to virus persistence in follow-up biopsies and survival rates over a 15-year period.

Results

Genotyping revealed a strong correlation between the CCR5del32 genotype and spontaneous virus clearance with improved outcomes. All patients with CCR5del32 eliminated EV spontaneously and none of them died within the observed period. In the group of untreated CCR5 wildtype patients, 33% died (Kaplan–Meier log-rank p = 0.010). However, CCR5 wildtype individuals treated with IFN-β are more likely to survive than without therapy (Kaplan–Meier log-rank p = 0.004) in identical proportions to individuals with the CCR5del32 genotype.

Conclusions

These data suggest that CCR5 genotyping is a novel predictive genetic marker for the clinical course of human EV cardiomyopathies. Hereby clinicians can identify those EV positive individuals who will eliminate the virus spontaneously based on CCR5 phenotype and those patients with CCR5 wildtype genotype who would be eligible for immediate antiviral IFN-β treatment to minimize irreversible cardiac damage.

Available only for authorised users

Why HJ, Meany BT, Richardson PJ, Olsen EG, Bowles NE, Cunningham L, et al. Clinical and prognostic significance of detection of enteroviral RNA in the myocardium of patients with myocarditis or dilated cardiomyopathy. Circulation. 1994;89:2582–9. https://doi.org/10.1161/01.CIR.89.6.2582.CrossRefPubMed

Cooper LT. Myocarditis. N Engl J Med. 2009;360:1526–38.CrossRefPubMedPubMedCentral

Caforio ALP, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felix SB, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013;34(2636–48):2648a–2648d. https://doi.org/10.1093/eurheartj/eht210.CrossRef

Kühl U, Pauschinger M, Noutsias M, Seeberg B, Bock T, Lassner D, et al. High prevalence of viral genomes and multiple viral infections in the myocardium of adults with “idiopathic” left ventricular dysfunction. Circulation. 2005;111:887–93. https://doi.org/10.1161/01.CIR.0000155616.07901.35.CrossRefPubMed

Kühl U, Pauschinger M, Seeberg B, Lassner D, Noutsias M, Poller W, et al. Viral persistence in the myocardium is associated with progressive cardiac dysfunction. Circulation. 2005;112:1965–70. https://doi.org/10.1161/CIRCULATIONAHA.105.548156.CrossRefPubMed

McManus BM, Yanagawa B, Rezai N, Luo H, Taylor L, Zhang M, et al. Genetic determinants of coxsackievirus B3 pathogenesis. Ann N Y Acad Sci. 2002;975:169–79. https://doi.org/10.1111/j.1749-6632.2002.tb05950.x.CrossRefPubMed

Maisch B, Pankuweit S. Standard and etiology-directed evidence-based therapies in myocarditis: state of the art and future perspectives. Heart Fail Rev. 2013;18:761–95.CrossRefPubMed

Kühl U, Pauschinger M, Schwimmbeck PL, Seeberg B, Lober C, Noutsias M, et al. Interferon-beta treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. Circulation. 2003;107:2793–8. https://doi.org/10.1161/01.CIR.0000072766.67150.51.CrossRefPubMed

Kühl U, Lassner D, von Schlippenbach J, Poller W, Schultheiss H-P. Interferon-beta improves survival in enterovirus-associated cardiomyopathy. J Am Coll Cardiol. 2012;60:1295–6. https://doi.org/10.1016/j.jacc.2012.06.026.CrossRefPubMed

10.

Schultheiss H-P, Piper C, Sowade O, Waagstein F, Kapp J-F, Wegscheider K, et al. Betaferon in chronic viral cardiomyopathy (BICC) trial: effects of interferon-β treatment in patients with chronic viral cardiomyopathy. Clin Res Cardiol. 2016;105:763–73. https://doi.org/10.1007/s00392-016-0986-9.CrossRefPubMed

11.

Bachelerie F, Ben-Baruch A, Burkhardt AM, Combadiere C, Farber JM, Graham GJ, et al. International Union of Pharmacology. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. Pharmacol Rev. 2014;66:1–79. https://doi.org/10.1124/pr.113.007724.CrossRefPubMedPubMedCentral

12.

Muntinghe FLH, Verduijn M, Zuurman MW, Grootendorst DC, Carrero JJ, Qureshi AR, et al. CCR5 deletion protects against inflammation-associated mortality in dialysis patients. J Am Soc Nephrol. 2009;20:1641–9. https://doi.org/10.1681/ASN.2008040432.CrossRefPubMedPubMedCentral

13.

Hütter G, Nowak D, Mossner M, Ganepola S, Müssig A, Allers K, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med. 2009;360:692–8. https://doi.org/10.1056/NEJMoa0802905.CrossRefPubMed

14.

Allers K, Hütter G, Hofmann J, Loddenkemper C, Rieger K, Thiel E, et al. Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation. Blood. 2011;117:2791–9. https://doi.org/10.1182/blood-2010-09-309591.CrossRefPubMed

15.

Lim JK, Murphy PM. Chemokine control of West Nile virus infection. Exp Cell Res. 2011;317:569–74. https://doi.org/10.1016/j.yexcr.2011.01.009.CrossRefPubMedPubMedCentral

16.

Hou P, Chen S, Wang S, Yu X, Chen Y, Jiang M, et al. Genome editing of CXCR4 by CRISPR/cas9 confers cells resistant to HIV-1 infection. Sci Rep. 2015;5:15577. https://doi.org/10.1038/srep15577.CrossRefPubMedPubMedCentral

17.

Afzal AR, Kiechl S, Daryani YP, Weerasinghe A, Zhang Y, Reindl M, et al. Common CCR5-del32 frameshift mutation associated with serum levels of inflammatory markers and cardiovascular disease risk in the Bruneck population. Stroke. 2008;39:1972–8. https://doi.org/10.1161/STROKEAHA.107.504381.CrossRefPubMed

18.

Lassner D, Siegismund CS, Stehr J, Rohde M, Escher F, Tschöpe C, et al. Recent advances in molecular diagnostics and treatment of heart muscle diseases. J Anal Sci Methods Instrum. 2013;2013(June):98–109.

19.

Schultheiss H-P, Kühl U, Cooper LT. The management of myocarditis. Eur Heart J. 2011;32:2616–25. https://doi.org/10.1093/eurheartj/ehr165.CrossRefPubMed

20.

Dörner A, Pauschinger M, Schwimmbeck PL, Kühl U, Schultheiss HP. The shift in the myocardial adenine nucleotide translocator isoform expression pattern is associated with an enteroviral infection in the absence of an active T-cell dependent immune response in human inflammatory heart disease. J Am Coll Cardiol. 2000;35:1778–84. https://doi.org/10.1016/S0735-1097(00)00644-6.CrossRefPubMed

21.

Pauschinger M, Phan MD, Doerner A, Kuehl U, Schwimmbeck PL, Poller W, et al. Enteroviral RNA replication in the myocardium of patients with left ventricular dysfunction and clinically suspected myocarditis. Circulation. 1999;99:889–95. https://doi.org/10.1161/01.CIR.99.7.889.CrossRefPubMed

22.

Lassner D, Kühl U, Rohde M, Siegismund CS, Schultheiss H-P. CCR5del32 polymorphism is a protective factor in non-ischemic cardiomyopathy. Int J Cardiol. 2014;173:561–2. https://doi.org/10.1016/j.ijcard.2014.03.123.CrossRefPubMed

23.

Pinto YM, Elliott PM, Arbustini E, Adler Y, Anastasakis A, Böhm M, et al. Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. Eur Heart J. 2016;37:1850–8. https://doi.org/10.1093/eurheartj/ehv727.CrossRefPubMed

24.

Rossol M, Pierer M, Arnold S, Keysser G, Burkhardt H, Baerwald C, et al. Negative association of the chemokine receptor CCR5 d32 polymorphism with systemic inflammatory response, extra-articular symptoms and joint erosion in rheumatoid arthritis. Arthritis Res Ther. 2009;11:R91. https://doi.org/10.1186/ar2733.CrossRefPubMedPubMedCentral

25.

Galvani AP, Slatkin M. Evaluating plague and smallpox as historical selective pressures for the CCR5-∆32 HIV-resistance allele. Proc Natl Acad Sci USA. 2003;100:15276–9. https://doi.org/10.1073/pnas.2435085100.CrossRefPubMed

26.

Goel MK, Khanna P, Kishore J. Understanding survival analysis: Kaplan–Meier estimate. Int J Ayurveda Res. 2010;1(4):274–8. https://doi.org/10.4103/0974-7788.76794.CrossRefPubMedPubMedCentral

27.

Bewick V, Cheek L. Ball. Statistics review 12: survival analysis. J Crit Care. 2004;8(5):389–94. https://doi.org/10.1186/cc2955 (Epub 2004 Sep 6).CrossRef

28.

Sleijfer S, Bannink M, Gool AR, Kruit WHJ, Stoter G. Side effects of interferon-α therapy. Pharm World Sci. 2005;27:423–31. https://doi.org/10.1007/s11096-005-1319-7.CrossRefPubMed

29.

Yajima T, Yasukawa H, Jeon E-S, Xiong D, Dorner A, Iwatate M, et al. Innate defense mechanism against virus infection within the cardiac myocyte requiring gp130-STAT3 signaling. Circulation. 2006;114:2364–73. https://doi.org/10.1161/CIRCULATIONAHA.106.642454.CrossRefPubMed

30.

Gorbea C, Makar KA, Pauschinger M, Pratt G, Bersola JLF, Varela J, et al. A role for Toll-like receptor 3 variants in host susceptibility to enteroviral myocarditis and dilated cardiomyopathy. J Biol Chem. 2010;285:23208–23. https://doi.org/10.1074/jbc.m109.047464.CrossRefPubMedPubMedCentral

31.

Valaperti A, Nishii M, Liu Y, Naito K, Chan M, Zhang L, et al. Innate immune interleukin-1 receptor-associated kinase 4 exacerbates viral myocarditis by reducing CCR5(+) CD11b(+) monocyte migration and impairing interferon production. Circulation. 2013;128:1542–54. https://doi.org/10.1161/CIRCULATIONAHA.113.002275.CrossRefPubMed

32.

Benkirane M, Jin D-Y, Chun RF, Koup RA, Jeang K-T. Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection by ccr5{Delta}32. J Biol Chem. 1997;272:30603–6. https://doi.org/10.1074/jbc.272.49.30603.CrossRefPubMed

33.

Schober A. Chemokines in vascular dysfunction and remodeling. Arterioscler Thromb Vasc Biol. 2008;28:1950–9. https://doi.org/10.1161/ATVBAHA.107.161224.CrossRefPubMed

34.

Schober A. Deposition of platelet RANTES triggering monocyte recruitment requires P-selectin and is involved in neointima formation after arterial injury. Circulation. 2002;106:1523–9. https://doi.org/10.1161/01.CIR.0000028590.02477.6F.CrossRefPubMed

35.

Candore G, Balistreri CR, Grimaldi MP, Listì F, Vasto S, Caruso M, et al. Opposite role of pro-inflammatory alleles in acute myocardial infarction and longevity: results of studies performed in a Sicilian population. Ann N Y Acad Sci. 2006;1067:270–5. https://doi.org/10.1196/annals.1354.035.CrossRefPubMed

36.

Berahovich RD, Miao Z, Wang Y, Premack B, Howard MC, Schall TJ. Proteolytic activation of alternative CCR1 ligands in inflammation. J Immunol. 2005;174:7341–51. https://doi.org/10.4049/jimmunol.174.11.7341.CrossRefPubMed

37.

Gong X, Gong W, Kuhns DB, Ben-Baruch A, Howard OM, Wang JM. Monocyte chemotactic protein-2 (MCP-2) uses CCR1 and CCR2B as its functional receptors. J Biol Chem. 1997;272:11682–5. https://doi.org/10.1074/jbc.272.18.11682.CrossRefPubMed

38.

Imai T, The T, Cell-directed CC. Chemokine TARC is a highly specific biological ligand for CC chemokine receptor 4. J Biol Chem. 1997;272:15036–42. https://doi.org/10.1074/jbc.272.23.15036.CrossRefPubMed

39.

Sirugo G, Predazzi IM, Bartlett J, Tacconelli A, Walther M, Williams SM. G6PD A-deficiency and severe malaria in The Gambia: heterozygote advantage and possible homozygote disadvantage. Am J Trop Med Hyg. 2014;90:856–9. https://doi.org/10.4269/ajtmh.13-0622.CrossRefPubMedPubMedCentral

Title: CCR5del32 genotype in human enteroviral cardiomyopathy leads to spontaneous virus clearance and improved outcome compared to wildtype CCR5
Authors: Dirk Lassner
Christine S. Siegismund
Uwe Kühl
Maria Rohde
Andrea Stroux
Felicitas Escher
Heinz-Peter Schultheiss
Publication date: 01-12-2018
Publisher: BioMed Central
Published in: Journal of Translational Medicine / Issue 1/2018
Electronic ISSN: 1479-5876
DOI: https://doi.org/10.1186/s12967-018-1610-8

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

CCR5del32 genotype in human enteroviral cardiomyopathy leads to spontaneous virus clearance and improved outcome compared to wildtype CCR5

Abstract

Background

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2018

A specific protocol of autologous bone marrow concentrate and platelet products versus exercise therapy for symptomatic knee osteoarthritis: a randomized controlled trial with 2 year follow-up

China Intracranial Aneurysm Project (CIAP): protocol for a registry study on a multidimensional prediction model for rupture risk of unruptured intracranial aneurysms

Increased circulating endothelial progenitor cells and improved short-term outcomes in acute non-cardioembolic stroke after hyperbaric oxygen therapy

iTRAQ-based quantitative analysis of age-specific variations in salivary proteome of caries-susceptible individuals

CCL20 is up-regulated in non-alcoholic fatty liver disease fibrosis and is produced by hepatic stellate cells in response to fatty acid loading

Gamma-delta (γδ) T cells: friend or foe in cancer development?

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page